Development of Nav1.7 Monoclonal Antibodies for Treating Pain
开发用于治疗疼痛的 Nav1.7 单克隆抗体
基本信息
- 批准号:10318547
- 负责人:
- 金额:$ 47.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAddressAffectAffinityAmericanAnimal ModelAnimalsAntibodiesAntibody AffinityAntibody TherapyBindingBiological AssayBiological AvailabilityBiosensorBlood - brain barrier anatomyCellsClinicClinical TrialsComplexDataDevelopmentDoseEngineeringEnvironmentEpitopesFamily memberGenerationsGenesGoalsHealthHumanImmunizationImmunizeIndustryIon ChannelKineticsLeadLidocaineLipidsLocationMeasuresMedicalMembrane PotentialsMembrane ProteinsMolecularMolecular ConformationMonoclonal AntibodiesN-formylmethionylphenylalanineNeuronsOpioidPainPeripheralPeripheral Nervous System DiseasesPhage DisplayPharmaceutical PreparationsPhaseProbabilityProtein EngineeringProteinsPublic HealthRoleSerumSmall Business Innovation Research GrantSodium ChannelSpecificityStructureTestingTherapeuticTherapeutic Monoclonal AntibodiesTimeLineVariantaddictionarmbaseburden of illnesschronic paindisabilitydisability burdenexperiencegain of function mutationheart functionhumanized monoclonal antibodiesimprovedloss of function mutationnon-opioid analgesicnovelopioid epidemicoverexpressionpain reliefpain sensationpain signalpatch clamppreclinical studyreceptorresponserisk minimizationsmall molecule inhibitorsmall molecule therapeuticstherapeutic developmentvoltage
项目摘要
ABSTRACT
Chronic pain is a significant medical problem, affecting over 50 million Americans and representing the largest
cause of disability and disease burden globally. Current pain relief treatments rely heavily on opioid drugs,
which are only partially effective and have a limited therapeutic window. Sustained use of opioids increases the
probability of misuse and addiction, which has led to the current opioid epidemic. Development of efficacious,
non-opioid analgesics could help mitigate this public health crisis and address a significant unmet medical
need. The voltage-gated sodium ion channel Nav1.7 is one of the primary components involved in pain signal
generation. Loss-of-function mutations in the gene encoding Nav1.7 (SCN9A) result in complete insensitivity to
pain in humans. Conversely, gain-of-function mutations contribute to painful peripheral neuropathies. Small
molecule inhibitors of Nav1.7, such as lidocaine, also validate the role of Nav1.7 in pain, but such molecules
cannot be used systemically because they also non-specifically inhibit other sodium channels such as Nav1.5
(required for cardiac function). Despite the remarkable role of Nav1.7 in pain sensation, drugs that specifically
block Nav1.7 have so far proven ineffective in clinical trials. Small molecule therapeutics lack channel subtype
selectivity, and poor bioavailability has made effective dosing difficult in clinical trials. Monoclonal antibodies
(MAbs) offer therapeutic advantages of improved specificity and bioavailability, but there are currently no good
MAbs against Nav1.7. Inhibitory MAbs against ion channels such as Nav1.7 are extremely challenging to
isolate because, unlike soluble proteins, ion channels form complex transmembrane structures, are toxic when
overexpressed, and are difficult to purify away from their native lipid environment. Here we propose to develop
Nav1.7 monoclonal antibodies for treating pain.
摘要
慢性疼痛是一个重大的医疗问题,影响超过5000万美国人,并代表了最大的
造成全球残疾和疾病负担。目前的疼痛缓解治疗严重依赖阿片类药物,
其仅部分有效并且具有有限的治疗窗。持续使用阿片类药物增加了
滥用和成瘾的可能性,导致目前的阿片类药物流行病。开发有效的,
非阿片类镇痛药可以帮助缓解这一公共卫生危机,并解决一个重大的未满足的医疗需求。
需要的电压门控钠离子通道Nav1.7是参与疼痛信号的主要成分之一
一代编码Nav1.7(SCN9A)的基因中的功能缺失突变导致对
人类的痛苦相反,功能获得性突变导致疼痛性周围神经病变。小
Nav1.7的分子抑制剂,如利多卡因,也证实了Nav1.7在疼痛中的作用,但这些分子
不能全身使用,因为它们也非特异性抑制其他钠通道,如Nav1.5
(心脏功能所需)。尽管Nav1.7在疼痛感觉中发挥了显著作用,但特异性抑制Nav1.7的药物
迄今为止,Nav1.7块在临床试验中被证明无效。小分子治疗缺乏通道亚型
选择性和差的生物利用度使得在临床试验中难以进行有效给药。单克隆抗体
单克隆抗体(MAb)提供了改善的特异性和生物利用度的治疗优势,但目前还没有良好的
针对Nav1.7的MAb。针对离子通道(如Nav1.7)的抑制性MAb对于抑制细胞内的细胞生长是极其具有挑战性的。
分离是因为与可溶性蛋白质不同,离子通道形成复杂跨膜结构,当
它们是过表达的,并且难以从它们的天然脂质环境中纯化。在这里,我们建议开发
用于治疗疼痛的Nav1.7单克隆抗体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH Benjamin RUCKER其他文献
JOSEPH Benjamin RUCKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH Benjamin RUCKER', 18)}}的其他基金
Development of Claudin MAbs for Treating Solid Tumors
用于治疗实体瘤的 Claudin MAb 的开发
- 批准号:
10482193 - 财政年份:2022
- 资助金额:
$ 47.48万 - 项目类别:
Development of Claudin MAbs for Treating Solid Tumors
用于治疗实体瘤的 Claudin MAb 的开发
- 批准号:
10631161 - 财政年份:2022
- 资助金额:
$ 47.48万 - 项目类别:
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
开发针对 TEM 细胞的 Kv1.3 单克隆抗体用于治疗自身免疫性疾病
- 批准号:
10374043 - 财政年份:2014
- 资助金额:
$ 47.48万 - 项目类别:
Development of High-expressing Ion Channels for Research and Therapeutic Applicat
用于研究和治疗应用的高表达离子通道的开发
- 批准号:
8775955 - 财政年份:2014
- 资助金额:
$ 47.48万 - 项目类别:
Development of High-expressing Ion Channels for Research and Therapeutic Applicat
用于研究和治疗应用的高表达离子通道的开发
- 批准号:
8920157 - 财政年份:2014
- 资助金额:
$ 47.48万 - 项目类别:
Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders
开发针对 TEM 细胞的 Kv1.3 单克隆抗体用于治疗自身免疫性疾病
- 批准号:
9906631 - 财政年份:2014
- 资助金额:
$ 47.48万 - 项目类别:
Isolation of Monoclonal Antibodies against Membrane Proteins
膜蛋白单克隆抗体的分离
- 批准号:
8057198 - 财政年份:2011
- 资助金额:
$ 47.48万 - 项目类别:
Development of P2X3 Ion Channel MAbs for the Treatment of Pain
开发用于治疗疼痛的 P2X3 离子通道单克隆抗体
- 批准号:
9130898 - 财政年份:2011
- 资助金额:
$ 47.48万 - 项目类别:
Isolation of Monoclonal Antibodies against Membrane Proteins
膜蛋白单克隆抗体的分离
- 批准号:
8215713 - 财政年份:2011
- 资助金额:
$ 47.48万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.48万 - 项目类别:
Research Grant